Study suggests monthly pegcetacoplan outperforms avacincaptad pegol in reducing GA lesion growth

A cross-trial comparison utilizing an anchored matching-adjusted indirect comparison (MAIC) suggests that monthly intravitreal pegcetacoplan (PEG) treatment may lead to a greater reduction in observed geographic atrophy (GA) lesion growth at Month 12 compared to avacincaptad pegol (ACP).

The results, presented at ASRS 2023, indicate a statistically significant 30.4% greater reduction in GA lesion growth with PEG compared to ACP when the data from multiple trials were combined using meta-analysis.

In the absence of a direct head-to-head trial, researchers conducted a comprehensive analysis using individual patient data (IPD) from two Phase 3 trials, OAKS and DERBY, which evaluated monthly 15 mg PEG versus sham injections. Aggregate data from the Phase 3 GATHER2 trial, examining monthly 2 mg ACP versus sham injections, was also included in the comparison.

The results revealed that in the OAKS versus GATHER2 comparison, PEG treatment led to a statistically significant 37.0% greater reduction in GA lesion growth compared to ACP. In the DERBY versus GATHER2 analysis, PEG also showed a numerically greater reduction (12.1%) in GA lesion growth, but the difference was not statistically significant.

However, when combining the results from both comparisons using meta-analysis, the pooled effect demonstrated a statistically significant 30.4% greater reduction in change in GA lesion growth with PEG compared to ACP.

A secondary analysis comparing patients treated with every other month (EOM) 15 mg PEG versus monthly 2 mg ACP showed comparable efficacy between the two groups.

Reference
Hahn P. Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy: An Anchored Matching-Adjusted Indirect Comparison of the Phase 3 Trials. Presented at: ASRS 41st Annual Meeting

This content is independent editorial sponsored by Astellas. Astellas had no input in the development of this content.